Medpace Holdings, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- August James Troendle
- Full Time Employees
- 6,200
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- 5375 Medpace Way Cincinnati OH United States 45227
- IPO Date
- Aug 11, 2016
- CIK
- 0001668397
- Website
- medpace.com
- Similar Companies
- Business
- Medpace Holdings, Inc. (Nasdaq: MEDP) is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries; core offerings encompass clinical trial management, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory services including central laboratories, bioanalytical laboratory, imaging core lab, ECG core lab, and Phase I clinical unit; the company operates its proprietary ClinTrak clinical trial management system to integrate study data and enhance efficiency. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace conducts operations across North America, Europe, Latin America, Asia Pacific, South America, Africa, and Australia, with a focus on complex trials in therapeutic areas such as oncology, cardiology, neurology, and infectious diseases, primarily serving small- to mid-sized biotech clients. In recent developments, the company reported record net new business awards of $789.6 million in Q3 2025, a 47.9% increase year-over-year, driving a net book-to-bill ratio of 1.20 and prompting upward revisions to 2025 revenue guidance to $2.48-$2.53 billion, reflecting 17.6%-20.0% growth over 2024 amid strong backlog momentum exceeding $3 billion; Medpace also projects low double-digit revenue growth and high single-digit EBITDA expansion for 2026, supported by strategic emphases on AI-enabled decentralized trials, oncology, and Phase III studies.
Company News
Madison Mid Cap Fund Q3 2026 Portfolio Activity
CON vs. MEDP: Which Stock Is the Better Value Option?
Medpace (MEDP) is a Great Momentum Stock: Should You Buy?
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run?
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"
All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy
Here's Why Medpace (MEDP) is a Strong Growth Stock
Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate
Medpace: 3 Key Takeaways for Long-Term Investors
Medpace Holdings, Inc. (MEDP) Q3 2026 Earnings Call Transcript
Medpace Q3 Earnings Call Highlights
Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates
A Look at Medpace Holdings Inc (MEDP) After 6.4% Gain -- GF Value $539.19 vs Price $662.48
Medpace Slips Despite Third-Quarter Beat, Solid Earnings Outlook
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
CON vs. MEDP: Which Stock Should Value Investors Buy Now?
Medpace (MEDP) Dips More Than Broader Market: What You Should Know
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
Medpace Holdings, Inc. $MEDP Stock Holdings Decreased by Argent Capital Management LLC